Institute for Clinical and Economic Review issues final cost effectiveness report on psoriasis agents that improves the value rating earlier assigned to novel treatments based on a consideration of actual net prices. Paid subscription required to read more. (Source: Cathy Kelly, Pink Sheet, 12/9/16)
You are here: Home / Cost Effectiveness / Does ICER’s Psoriasis Drug Valuation Undercut Routine Step Therapy?
